Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis

Acute promyelocytic leukemia (APL) is a rare acute leukemia generally considered curable with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Some patients have co-morbidities that may limit the use of these agents and therefore impact curability. Adverse effects of ATO include life-threa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tinajero, Jose, El-Shami, Khaled, Wu, Xiaojun, Smith, B. Douglas, Newman, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968060/
https://www.ncbi.nlm.nih.gov/pubmed/35371914
http://dx.doi.org/10.1016/j.lrr.2022.100304
_version_ 1784678965451948032
author Tinajero, Jose
El-Shami, Khaled
Wu, Xiaojun
Smith, B. Douglas
Newman, Matthew J.
author_facet Tinajero, Jose
El-Shami, Khaled
Wu, Xiaojun
Smith, B. Douglas
Newman, Matthew J.
author_sort Tinajero, Jose
collection PubMed
description Acute promyelocytic leukemia (APL) is a rare acute leukemia generally considered curable with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Some patients have co-morbidities that may limit the use of these agents and therefore impact curability. Adverse effects of ATO include life-threatening electrocardiographic abnormalities. ATO and its metabolites are partially excreted in the urine, and it is unclear to what extent ATO pharmacokinetics are impacted by hemodialysis. We present a patient on chronic hemodialysis successfully treated with ATO and ATRA for newly diagnosed APL. Complete molecular remission was achieved after induction and several drug-related toxicities were managed.
format Online
Article
Text
id pubmed-8968060
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-89680602022-04-01 Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis Tinajero, Jose El-Shami, Khaled Wu, Xiaojun Smith, B. Douglas Newman, Matthew J. Leuk Res Rep Article Acute promyelocytic leukemia (APL) is a rare acute leukemia generally considered curable with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Some patients have co-morbidities that may limit the use of these agents and therefore impact curability. Adverse effects of ATO include life-threatening electrocardiographic abnormalities. ATO and its metabolites are partially excreted in the urine, and it is unclear to what extent ATO pharmacokinetics are impacted by hemodialysis. We present a patient on chronic hemodialysis successfully treated with ATO and ATRA for newly diagnosed APL. Complete molecular remission was achieved after induction and several drug-related toxicities were managed. Elsevier 2022-03-25 /pmc/articles/PMC8968060/ /pubmed/35371914 http://dx.doi.org/10.1016/j.lrr.2022.100304 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Tinajero, Jose
El-Shami, Khaled
Wu, Xiaojun
Smith, B. Douglas
Newman, Matthew J.
Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis
title Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis
title_full Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis
title_fullStr Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis
title_full_unstemmed Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis
title_short Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis
title_sort arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968060/
https://www.ncbi.nlm.nih.gov/pubmed/35371914
http://dx.doi.org/10.1016/j.lrr.2022.100304
work_keys_str_mv AT tinajerojose arsenictrioxideforacutepromyelocyticleukemiainapatientonchronichemodialysis
AT elshamikhaled arsenictrioxideforacutepromyelocyticleukemiainapatientonchronichemodialysis
AT wuxiaojun arsenictrioxideforacutepromyelocyticleukemiainapatientonchronichemodialysis
AT smithbdouglas arsenictrioxideforacutepromyelocyticleukemiainapatientonchronichemodialysis
AT newmanmatthewj arsenictrioxideforacutepromyelocyticleukemiainapatientonchronichemodialysis

Ejemplares similares